JP2022512541A5 - - Google Patents

Info

Publication number
JP2022512541A5
JP2022512541A5 JP2021511588A JP2021511588A JP2022512541A5 JP 2022512541 A5 JP2022512541 A5 JP 2022512541A5 JP 2021511588 A JP2021511588 A JP 2021511588A JP 2021511588 A JP2021511588 A JP 2021511588A JP 2022512541 A5 JP2022512541 A5 JP 2022512541A5
Authority
JP
Japan
Prior art keywords
domain
cancer
binding
pharmaceutical composition
extracellular domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048923 external-priority patent/WO2020047328A1/en
Publication of JP2022512541A publication Critical patent/JP2022512541A/ja
Publication of JP2022512541A5 publication Critical patent/JP2022512541A5/ja
Pending legal-status Critical Current

Links

JP2021511588A 2018-08-29 2019-08-29 Pd-1系キメラタンパク質を含む併用療法 Pending JP2022512541A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862724600P 2018-08-29 2018-08-29
US62/724,600 2018-08-29
US201862734951P 2018-09-21 2018-09-21
US62/734,951 2018-09-21
US201962793235P 2019-01-16 2019-01-16
US62/793,235 2019-01-16
US201962832830P 2019-04-11 2019-04-11
US62/832,830 2019-04-11
US201962890217P 2019-08-22 2019-08-22
US62/890,217 2019-08-22
PCT/US2019/048923 WO2020047328A1 (en) 2018-08-29 2019-08-29 Combination therapies comprising pd-1-based chimeric proteins

Publications (2)

Publication Number Publication Date
JP2022512541A JP2022512541A (ja) 2022-02-07
JP2022512541A5 true JP2022512541A5 (cg-RX-API-DMAC7.html) 2022-09-06

Family

ID=69644684

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511588A Pending JP2022512541A (ja) 2018-08-29 2019-08-29 Pd-1系キメラタンパク質を含む併用療法
JP2021511586A Ceased JP2022511286A (ja) 2018-08-29 2019-08-29 Sirpアルファ系キメラタンパク質を含む併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021511586A Ceased JP2022511286A (ja) 2018-08-29 2019-08-29 Sirpアルファ系キメラタンパク質を含む併用療法

Country Status (9)

Country Link
US (3) US20210379153A1 (cg-RX-API-DMAC7.html)
EP (2) EP3844176A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512541A (cg-RX-API-DMAC7.html)
CN (2) CN112771067A (cg-RX-API-DMAC7.html)
AU (2) AU2019327493A1 (cg-RX-API-DMAC7.html)
CA (2) CA3109354A1 (cg-RX-API-DMAC7.html)
IL (2) IL281095A (cg-RX-API-DMAC7.html)
MX (2) MX2021002292A (cg-RX-API-DMAC7.html)
WO (2) WO2020047328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278865B (zh) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
MX2021002292A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
US20210301019A1 (en) * 2020-03-26 2021-09-30 Aetio Biotherapy, Inc. Bi-specific fusion proteins for depletion of regulatory t cells
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
IL301454A (en) * 2020-09-17 2023-05-01 Shattuck Labs Inc Clinical dosing of SIRP1A chimeric protein
US20230414778A1 (en) * 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
AU2021390545A1 (en) * 2020-12-03 2023-07-06 Shattuck Labs, Inc. Methods of treating cancer using tigit-and light-based chimeric proteins
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
CN117355336A (zh) * 2021-03-05 2024-01-05 沙塔克实验室有限公司 基于SIRP α的嵌合蛋白的联合疗法
JP2024508540A (ja) * 2021-03-05 2024-02-27 シャタック ラボ,インコーポレイテッド SIRPαベースのキメラタンパク質を用いた併用療法
MX2024005649A (es) * 2021-11-12 2024-07-10 Shattuck Labs Inc Proteinas quimericas basadas en sirp1a y cd40l.
CN120923632A (zh) * 2022-05-06 2025-11-11 正大天晴药业集团股份有限公司 靶向cd40和cd47的重组融合蛋白
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体,その使用方法および遺伝子治療のための分子スイッチ
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
ME03550B (me) * 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
PE20151921A1 (es) * 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
DK3565579T3 (da) * 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL268198B2 (en) 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
MX2021002292A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.

Similar Documents

Publication Publication Date Title
JP2022511286A5 (cg-RX-API-DMAC7.html)
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
JP2024532485A (ja) Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質
AU2017247880B2 (en) Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion
JP2023509323A5 (cg-RX-API-DMAC7.html)
JP2024125370A (ja) クローディン18.2結合部分およびその利用
JP7102670B2 (ja) 抗pd‐l1抗体とil‐7との融合
JP6840127B2 (ja) がんの治療における抗pd−1抗体および抗m−csf抗体の併用
JP7464525B2 (ja) 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質
JP2020530298A5 (cg-RX-API-DMAC7.html)
US20160235842A1 (en) Medical uses of cd38 agonists
JP2017506217A (ja) 標的TGFβ阻害
CA3146777A1 (en) Anti-pd-1 antibody and pharmaceutical use thereof
US20240018248A1 (en) An ltbr agonist in combination therapy against cancer
JP7362614B2 (ja) 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
CN115192718A (zh) 抗cd47的单克隆抗体及其用途
AU2017239038B2 (en) Administration of an anti-LGR5 monoclonal antibody
JP2022512539A5 (cg-RX-API-DMAC7.html)
CN115197325A (zh) 抗体在抗肿瘤治疗中的用途
JP2025118769A5 (cg-RX-API-DMAC7.html)
CN119403831A (zh) 包含nrp1结合结构域的双特异性抗体及其使用方法
WO2019053613A2 (en) POLY THERAPY FOR THE TREATMENT OF CANCER
CN114616251A (zh) 靶向PD-1和TGFβ的重组蛋白
JP7832689B2 (ja) Pd-1ポリペプチド変異体
JP2022503621A5 (cg-RX-API-DMAC7.html)